Local recurrence of breast cancer (LRBC)

Local recurrence of breast cancer is frequently a therapeutic challenge.
In case of pre-irradiation, effective tumour control by reirradiation faces the risk of cumulative radiotoxicity. These heavily pretreated patients are often also resistant to systemic therapies such as chemo- and hormonetherapy, or the side-effects of these therapies must be taken into consideration along with the limited anti-tumour effects that can be expected.

In 2005, Jones et al. published a randomised study of HT/RT compared to RT alone in superficial tumours. The CR rate in the combined HT/RT group was 66% compared to 42% in the RT group alone. A significantly higher CR rate was shown in patients who had previously been irradiated: 68% compared to 28%.

A recent Systematic Review and Meta-Analysis published by Datta N et al. in the International Journal of Radiation Oncology ((Vol. 94, No. 5, pp. 1073-1087, 2016) showed the efficacy of the combined HT/RT in the treatment of LRBC proven by randomized and single-arm clinical studies. In most of the studies the CR rate of pre-irradiated LRBC was between 60 and 70%.

For treatment results with hydrosun®TWH1500 go to menu Clinical results




Print Email

heckel medizintechnik GmbH

Olgastrasse 25
73728 Esslingen

Tel: ++49 (0)711 - 128989 - 0



Visit us on Facebook

Visit us on Linkedin





We use cookies on our website. Some of them are essential for the operation of the site, while others help us to improve this site and the user experience (tracking cookies). You can decide for yourself whether you want to allow cookies or not. Please note that if you reject them, you may not be able to use all the functionalities of the site.